Compare Inovio Pharmaceuticals Inc (INO) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Victoria's Secret & Co — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Victoria's Secret & Co trades at $94.16 (market cap $7.48B). The key difference: Victoria's Secret & Co is far larger — about 95.2× Inovio Pharmaceuticals Inc's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | VSXY | |
|---|---|---|
Market Cap | $78.55M | $7.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $99.97 |
52-Week Low | $0.66 | $21.34 |
Enterprise Value | $49.56M | $10.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Victoria's Secret (VSXY) trades at $92.97, down 7.0% on the day but maintains strong technical momentum with bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive cash flow projections for 2026. Recent news highlights international expansion success, particularly in China, and data-driven marketing initiatives driving growth.
The stock presents a balanced opportunity with analyst consensus favoring Buy ratings (55.6%) and a $91 price target near current levels. Key risks include competitive pressures in apparel retail and margin volatility, while catalysts include continued international growth and potential earnings surprises in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
